In this special episode of This Week in Pharmacy, we dive into one of the most debated topics in healthcare today: GLP-1 receptor agonists. Joining the discussion are Josh Pirestani, Editor-in-Chief of Dispense Times; Dr. Darshan Kulkarni, PharmD, of Kulkarni Law Firm; and Dr. Masoud Rashidi, PharmD, FAPC, CEO of Innovative Compounding Pharmacy.

Whether you see the latest weight loss drugs as a miracle or a menace, the hype around GLP-1s is impossible to ignore. What started with Ozempic, a diabetes treatment, quickly shifted into a global weight-loss trend. Soon after, Wegovy, a high-dose version officially marketed for obesity, took center stage. The popularity of these medications skyrocketed, catapulting their manufacturer’s market value beyond the entire economy of Denmark. And now, Eli Lilly's Zepbound has entered the competitive landscape.

Our expert panel explores the current state of GLP-1s, discussing:

✅ The clinical impact and efficacy of these drugs

✅ Safety concerns and side effects

✅ Ethical considerations surrounding off-label use

✅ The skyrocketing demand and supply shortages

✅ How compounding pharmacies are navigating the GLP-1 surge

With soaring demand and increasing controversy, the conversation around these medications is far from over. Tune in for an insightful discussion on what’s next for GLP-1 receptor agonists and the future of weight loss treatments.

🎧 Listen now and stay informed on the latest pharmacy trends!